|  |
| --- |
| **Table 1**. Baseline characteristics of the studied population (n = 241) |
|   |   |   |   |
| Clinical data | **Age** (year) |  |  |
| mean ± sd | 24.8 | ± 15.6 |
| median *(iqr)* | 19 | *(24)* |
| **Sex**, n *(%)* |  |  |
| *Men* | 111 | *(46.1)* |
| *Women* | 130 | *(53.9)* |
| **SCD Status**, n *(%)* |  |  |
| *SS* | 138 | *(57.3)* |
| *SC* | 103 | *(42.7)* |
| **HU*a* treatment**, n *(%)* |  |  |
| *treated* | 33 | *(13.7)* |
| *non-treated* | 208 | *(86.3)* |
| Biological parameters | **NOx***b* (µmol.l-1) |   |   |
| mean ± sd | 30.8 | ± 10.4 |
| Hemorheological parameters  | **EI***c* (a.u.) |   |   |
| *mean ± sd* | 0.396 | ± 0.1 |
| *median (iqr)* | 0.408 | *(0.131)* |
| **AI***d* (%)  |  |  |
| mean ± sd | 49.3 | ± 9.8 |
| **γ***e* (s-1) |  |  |
| *mean ± sd* | 282.3 | ± 112.9 |
| *median (iqr)* | 275 | *(155)* |
| **Blood viscosity** (cP) *mean ± sd* |  |  |
| *225s*  | 6.3 | ± 1.4 |
| *90s*  | 8.2 | ± 2.3 |
| eNOS Polymorphisms  | **VNTR**, n *(%)* |  |  |
| *44* | 21 | *(8.8)* |
| *45* | 101 | *(42.1)* |
| *55* | 105 | *(43.7)* |
| *56* | 12 | *(5.0)* |
| *66* | 1 | *(0.4)* |
| **-786TC**, n *(%)* |  |  |
| *TT* | 162 | *(69.8)* |
| *TC* | 69 | *(29.8)* |
| *CC* | 1 | *(0.4)* |
| **894GT**, n *(%)* |  |  |
| *GG* | 198 | *(84.2)* |
| *GT* | 35 | *(14.9)* |
| *TT* | 2 | *(0.9)* |
| *a*Hydroxyurea, bNitric oxide end-products, cElongation Index (i.e., RBC deformability), dRBC Aggregation Index, eRBC Disaggregation threshold |
| SCD patients: sickle cell anemia patients (138) and sickle cell hemoglobin C patients (103) ;VNTR: variable number of tandem DNA repeats |

 Quantitative data are expressed as mean (± standard deviation/±sd) or median (interquartile range/iqr)

 Qualitative date are expressed as number *(percentage/%)*